Dobutamine
Dobutamine is a synthetic catecholamine primarily used as an inodilator in ICU practice.
1. Pharmacology & Receptor Profile
Mechanism of Action
- β1-adrenergic agonist (predominant) → ↑ myocardial contractility
- Mild β2 activity → peripheral vasodilation
- Minimal α1 effect (balanced by β2 effect)
Unlike dopamine, it has no significant dopaminergic renal effect.
2. Hemodynamic Effects
|
Parameter |
Effect |
|
Cardiac Output |
↑↑ |
|
Stroke Volume |
↑↑ |
|
Heart Rate |
Mild ↑ |
|
SVR |
↓ (mild to moderate) |
|
Pulmonary Vascular Resistance |
↓ |
|
MAP |
Variable (may fall if vasodilatory effect dominates) |
|
Myocardial O2 consumption |
↑ |
In hypotensive patients, dobutamine may worsen hypotension → often combined with norepinephrine.
3. Dose range:
- 2–5 mcg/kg/min → low inotropic effect
- 5–10 mcg/kg/min → standard ICU dose
- 10–20 mcg/kg/min → increased tachyarrhythmia risk
No renal dose adjustment required.
4. Indications in Critical Care
A. Cardiogenic Shock (Most Important)
Used in:
- Acute MI with low cardiac output
- Decompensated heart failure
- Post-cardiotomy low-output state
- Myocarditis
Guideline Position
- ESC Cardiogenic Shock guidelines: Dobutamine preferred in low-output state with adequate MAP.
- Surviving Sepsis Campaign: Add dobutamine if:
- Persistent hypoperfusion despite fluids + norepinephrine
- Myocardial dysfunction with low cardiac output
B. Septic Shock with Myocardial Dysfunction
When:
- Low ScvO₂ despite adequate MAP
- Echo shows depressed LV function
Used as add-on to norepinephrine, not monotherapy.
C. Right Ventricular Failure
Useful in:
- RV infarction
- Pulmonary hypertension with low output
- Massive PE (careful use)
Because:
- Improves contractility
- Reduces PVR (via β2 effect)
D. Stress Echocardiography
Pharmacologic stress testing agent (non-ICU indication).
5. Comparison with Other Inotropes
|
Drug |
Inotropy |
Vasodilation |
Best Use |
|
Dobutamine |
Strong |
Mild |
Cardiogenic shock |
|
Dopamine |
Moderate |
Dose-dependent |
Bradycardia + shock |
|
Milrinone |
Strong |
Strong |
Pulmonary HTN, RV failure |
|
Epinephrine |
Strong |
Variable |
Refractory shock |
6. Adverse Effects
- Tachycardia
- Atrial fibrillation
- Ventricular arrhythmias
- Hypotension (vasodilatory effect)
- Myocardial ischemia
- Tolerance after 48–72 hrs (β-receptor downregulation)
Avoid in:
- Hypertrophic obstructive cardiomyopathy (increases LVOT obstruction)
- Uncontrolled arrhythmias
7. Hemodynamic Monitoring in ICU
Should be guided by:
- Echo (LV/RV function)
- Cardiac output monitoring (PiCCO, PAC, FloTrac)
- Lactate trends
- ScvO₂
- Urine output
Target:
✔ CI > 2.2 L/min/m²
✔ Improving lactate
✔ End-organ perfusion
8. Dobutamine vs Milrinone
|
Feature |
Dobutamine |
Milrinone |
|
Mechanism |
β1 agonist |
PDE-3 inhibitor |
|
Renal adjustment |
No |
Yes |
|
Onset |
Rapid |
Slower |
|
Hypotension risk |
Moderate |
High |
|
Best in |
Acute shock |
Chronic HF, RV failure |
|
Arrhythmias |
Common |
Less than dobutamine |
